Adolph V, Arensman R M, Falterman K W, Goldsmith J P
Department of Pediatrics, Ochsner Clinic, New Orleans, Louisiana 70121.
J Perinatol. 1990 Jun;10(2):202-5.
Respiratory distress in newborns with CDH is the result of the interaction of pulmonary hypertension and pulmonary hypoplasia. Many patients will demonstrate adequate pulmonary parenchyma after repair as evidenced by adequate oxygenation and ventilation. Patients should be classified into groups of predicted mortality using Bohn's criteria. Patients in groups A, B, and D may be managed conventionally if blood gases can be kept in the normal range. These patients should be supported with ECMO if unresponsive to conventional management. In those patients with adequate gas exchange who fall into the C group, transfer to an ECMO center should be undertaken early, since mortality with continued conventional management is predictable. Some patients never demonstrate a "honeymoon" period, and mortality can be reliably predicted in this group as well by using Bohn's criteria. Because the relative significance of pulmonary hypoplasia compared with pulmonary hypertension in an individual patient cannot be reliably determined, any patient who has respiratory failure after repair of CDH should be supported with ECMO when conventional techniques fail as long as no contraindications exist. At least one institution will withhold ECMO therapy if lung parenchyma is judged inadequate as predicted by the inability to achieve a preductal PaO2 greater than 100 mm Hg and PaCO2 less than 50 mm Hg with maximal conventional therapy. In our experience, however, some patients can survive with ECMO support when all other indicators would suggest hypoplasia incompatible with life. Therefore, we do not believe any patient should be refused ECMO support when conventional measures fail.(ABSTRACT TRUNCATED AT 250 WORDS)
先天性膈疝(CDH)新生儿的呼吸窘迫是肺动脉高压和肺发育不全相互作用的结果。许多患者在修复术后肺实质功能良好,表现为氧合和通气充足。应根据博恩标准将患者分为预测死亡率组。如果血气能维持在正常范围,A、B和D组患者可采用传统方法治疗。如果对传统治疗无反应,这些患者应接受体外膜肺氧合(ECMO)支持。对于气体交换良好且属于C组的患者,应尽早转至ECMO中心,因为持续采用传统治疗的死亡率是可预测的。一些患者从未出现“蜜月期”,使用博恩标准也可可靠预测该组患者的死亡率。由于无法可靠确定个体患者中肺发育不全与肺动脉高压的相对重要性,只要没有禁忌证,任何CDH修复术后出现呼吸衰竭且传统技术无效的患者都应接受ECMO支持。至少有一家机构如果根据最大传统治疗仍无法使导管前血氧分压大于100 mmHg且二氧化碳分压小于50 mmHg判断肺实质功能不足,就会停止ECMO治疗。然而,根据我们的经验,有些患者在所有其他指标都表明肺发育不全无法存活的情况下,仍可在ECMO支持下存活。因此,我们认为当传统措施无效时,不应拒绝任何患者接受ECMO支持。(摘要截选至250字)